Sage Journals: Discover world-class research

Abstract

Blood-borne RNA circulating in association with autoantibodies is a potent stimulator of interferon production and immune system activation. RSLV-132 is a novel fully human biologic Fc fusion protein that is comprised of human RNase fused to the Fc domain of human IgG1. The drug is designed to remain in circulation and digest extracellular RNA with the aim of preventing activation of the immune system via Toll-like receptors and the interferon pathway. The present study describes the first clinical study of nuclease therapy in 32 subjects with systemic lupus erythematosus. The drug was well tolerated with a very favorable safety profile. The approximately 19-day serum half-life potentially supports once monthly dosing. There were no subjects in the study that developed anti-RSLV-132 antibodies. Decreases in B-cell activating factor correlated with decreases in disease activity in a subset of patients.

Keywords

RNA immune complex nuclease therapy interferon

Get full access to this article

View all access options for this article.

References

Shao

Cohen

. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: 202–202.

Arbuckle

McClain

Rubertone

. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526–1533.

Von Muhlen

Tan

. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995; 24: 323–358.

Kattah

Utz

. The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol Rev 2010; 233: 126–145.

Lau

Broughton

Tabor

. RNA-associated autoantigens activate B cells by combined B cell receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202: 1171–1177.

Vollmer

Tluk

Schmitz

. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2006; 202: 1575–1585.

Leadbetter

Rifkin

Hohlbaum

. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603–607.

Lovgren

Eloranta

Bave

Alm

Ronnblom

. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50: 1861–1872.

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

10.

Hochberg

. for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725–1725.

11.

Kennedy

Maciuca

Wolslegel

. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci Med 2015; 2: e000080–e000080.

12.

Lobo

Hansen

Balthasar

. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645–2648.

13.

Sahin

Benet

. The operational multiple dosing half-life: A key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 2008; 25: 2869–2877. DOI: 10.1007/s11095-008-9787-9.

14.

Hua

Kirou

Lee

Crow

. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906–1916.

15.

Ahlin

Mathsson

Eloranta

. Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE. Lupus 2012; 21: 586–595.

16.

Barrat

Elkon

Fitzgerald

. Importance of nucleic acid recognition in inflammation and autoimmunity. Annu Rev Med 2016; 67: 323–336. DOI: 10.1146/annrev-med-052814-023338.

17.

Bave

Vallin

Alm

Ronnblom

. Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001; 17: 71–80.

18.

Marshak-Rothstein

Rifkin

. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007; 25: 419–441.

19.

Santer

Yoshio

Minota

Moller

Elkon

. Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol 2009; 182: 1192–1201.

20.

Weickmann

Glitz

. Human ribonucleases. Quantitation of pancreatic-like enzymes in serum, urine, and organ preparations. J Biol Chem 1982; 257: 8705–8710.

21.

Poon

Lucas

Rossi

. Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol 2014; 14: 166–180.

22.

Chaussabel

Quinn

Shen

. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008; 29: 150–164.

23.

Chiche

Jourde-Chiche

Whalen

. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014; 66: 1583–1595.

24.

Khamashta

Merrill

Werth

. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study. Ann Rheum Dis 2016; 75: 1909–1916. DOI: 10.1136/annrheumdis-2015-208562.

25.

Morehouse

Brohawn

Higgs

. Pharmacokinetics of sifalimumab and target modulation of a type I interferon gene signature in patients with moderate to severe systemic lupus erythematosus. Ann Rheum Dis 2015; 74: 946. DOI: 10.1136/annrheumdis-2015-eular.4529.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.16 MB

Safety,pharmacokinetics,and pharmacodynamics of RSLV-132,an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized,double-blind,placebo-controlled study

Abstract

Keywords

Get full access to this article

References

Supplementary Material